Skip to main content

Portfolio

Investment Principles
Investment Area
Investment Process
Portfolio

*WHO licensure prequalification

Vaccines(Vx), Therapeutics(Tx)
Focus field Project title Research institute Development stage
Pre-clinical Phase1 Phase2 Phase3 Licensure
Vaccines (Vx) Low-cost HepAVaccine Manufacturing Platform ●
Novel Cholera Conjugate Vaccine ●
Pentavalent Meningitis Conjugate Vaccine ● ● ●
Prime-Boost BCG Vaccine ●
Development of a sublingual COVID-19 subunit vaccine ●
Schistosomiasis vaccine ● ●
Typhoid Conjugate Vaccine ● ●
Measles-Rubella MAP vaccine ●
Group A Streptococcus vaccine ●
Therapeutics (Tx) Continuous Manufacturing Process for New Antimalarial ● ●
Antimalarial combination therapy for malaria prevention ● ●
Development of a therapeutic anti-dengue polymeric IgG antibody ●
Continuous manufacturing process for visceral leishmaniasis drug ●
Continuous manufacturing process for human use helminth infection treatment ● ●
Novel antibiotic combinations to address AMR burden in neonatal sepsis ●
Treatment development for severe malaria ●
Single exposure radical cure for blood stage malaria ●
Diagnostics(Dx), Digital Health(DH)
Focus field Project title Research institute Development stage
Early Validation Late Validation Clinical Validation Licensure
Diagnostics (Dx) Leishmaniasis RDT Cartridge and Mobile Pocket Analyzer ●
AI-driven All-in-One Diagnostic platform for Malaria Species Differentiation ● ●
In vitro Diagnostics Test for Severe Fever and thrombocytopenia Syndrome ●
POCT for Pyrazinamide (PZA) Susceptibility Testing ●
POCT for Multidrug-Resistant TB ● ●
POCT for COVID19, Influenza and RSV ● ● ●

*WHO licensure prequalification

Vaccines(Vx)
Project title Research institute Development stage Current state
Pre-clinical Phase1 Phase2 Phase3 Licensure
DTwP-HepB-Hib Pentavalent MAP Vaccine ● Completed
Low-cost HepAVaccine Manufacturing Platform ● Completed
Prime-Boost BCG Vaccine ● Suspended
COVID-19 Vaccine Using Viral Vector System ● Completed
DNA Vaccine Using Electro-Portable MicroneedlePatch ● Completed
Intranasal Universal Respiratory Virus Vaccine ● Completed
Microneedle-mediated SARS-CoV-2 DNA Vaccine ● Completed
Mpg loaded TB MAP Vaccine ● Completed
Non-replicating Protein Nanoparticles-based Rotavirus Vaccine ● Completed
SARS-CoV-2 Nanogel Sublingual Vaccine ● Suspended
Virus-free Recombinant Polio Vaccine ● Suspended
Development of a sublingual COVID-19 subunit vaccine ● Completed
Novel Cholera Conjugate Vaccine ● Completed
Quadrivalent Meningitis Conjugate Vaccine ● ● ● Suspended
Pentavalent Meningitis Conjugate Vaccine ● ● ● In progress
Schistosomiasis vaccine ● ● In progress
DTwP-HepB-IPV-Hib Hexavalent Vaccine ● ● Completed
Typhoid Conjugate Vaccine ● ● In progress
Measles-Rubella MAP vaccine ● In progress
Group A Streptococcus vaccine ● In progress

*WHO licensure prequalification

Vaccines(Vx)
Project title Research institute Development stage
Pre-clinical Phase1 Phase2 Phase3 Licensure
Low-cost HepAVaccine Manufacturing Platform ●
DTwP-HepB-Hib Pentavalent MAP Vaccine ●
Novel Cholera Conjugate Vaccine ●
COVID-19 Vaccine Using Viral Vector System ●
DNA Vaccine Using Electro-Portable MicroneedlePatch ●
Intranasal Universal Respiratory Virus Vaccine ●
Microneedle-mediated SARS-CoV-2 DNA Vaccine ●
Mpg loaded TB MAP Vaccine ●
Non-replicating Protein Nanoparticles-based Rotavirus Vaccine ●
DTwP-HepB-IPV-Hib Hexavalent Vaccine ● ●
Measles-Rubella MAP vaccine ●

*WHO licensure prequalification

Vaccines(Vx)
Project title Research institute Development stage
Pre-clinical Phase1 Phase2 Phase3 Licensure
Pentavalent Meningitis Conjugate Vaccine ● ● ●
Schistosomiasis vaccine ● ●
Typhoid Conjugate Vaccine ● ●
Measles-Rubella MAP vaccine ●
Group A Streptococcus vaccine ●

*WHO licensure prequalification

Vaccines(Vx)
Project title Research institute Development stage
Pre-clinical Phase1 Phase2 Phase3 Licensure
SARS-CoV-2 Nanogel Sublingual Vaccine ●
Virus-free Recombinant Polio Vaccine ●
Quadrivalent Meningitis Conjugate Vaccine ● ● ●
Prime-Boost BCG Vaccine ●

*WHO licensure prequalification

Therapeutics(Tx)
Project title Research institute Development stage Current state
Pre-clinical Phase1 Phase2 Phase3 Licensure
Development of a therapeutic anti-dengue polymeric IgG antibody ● Suspended
NiclosamideIntramuscularDepotInjectionfor Dengue VirusDisease ● Suspended
Safety assessment of TTCA antitubercular agents ● Completed
Novel route of synthesis of antimalarial drug ● ● Suspended
Antimalarial combination therapy for malaria prevention ● ● In progress
Continuous manufacturing process for visceral leishmaniasis drug ● Completed
Continuous Manufacturing Process for New Antimalarial ● ● Completed
Continuous manufacturing process for human use helminth infection treatment ● ● In progress
Novel antibiotic combinations to address AMR burden in neonatal sepsis ● In progress
Treatment development for severe malaria ● In progress
Single exposure radical cure for blood stage malaria ● In progress

*WHO licensure prequalification

Therapeutics(Tx)
Project title Research institute Development stage
Pre-clinical Phase1 Phase2 Phase3 Licensure
Safety assessment of TTCA antitubercular agents ●
Continuous manufacturing process for visceral leishmaniasis drug ●
Continuous Manufacturing Process for New Antimalarial ● ●

*WHO licensure prequalification

Therapeutics(Tx)
Project title Research institute Development stage
Pre-clinical Phase1 Phase2 Phase3 Licensure
Antimalarial combination therapy for malaria prevention ● ●
Continuous manufacturing process for human use helminth infection treatment ● ●
Novel antibiotic combinations to address AMR burden in neonatal sepsis ●
Treatment development for severe malaria ●
Single exposure radical cure for blood stage malaria ●

*WHO licensure prequalification

Therapeutics(Tx)
Project title Research institute Development stage
Pre-clinical Phase1 Phase2 Phase3 Licensure
NiclosamideIntramuscularDepotInjectionfor Dengue VirusDisease ●
Novel route of synthesis of antimalarial drug ● ●
Development of a therapeutic anti-dengue polymeric IgG antibody ●

*WHO licensure prequalification

Diagnostics(Dx)
Project title Research institute Development stage Current state
Early Validation Late Validation Clinical Validation Licensure
Leishmaniasis RDT Cartridge and Mobile Pocket Analyzer ● Suspended
In vitro Diagnostics Test for Severe Fever and thrombocytopenia Syndrome ● Suspended
Instrument-free molecular diagnostic platform for COVID-19 ● ● Completed
Mobile Diagnostic Platform for Influenza and SARS-CoV-2 ● ● Completed
POCT for Pyrazinamide (PZA) Susceptibility Testing ● Completed
Quantitative POC Test Using mBFPfor G6PD Deficiency ● Completed
Rapid Diagnostic Test for Both S.Typhiand S.ParatyphiA ● ● Suspended
Rapid Diagnostic Test for Chikungunya Antigen ● Completed
Rapid Diagnostic Test for Visceral Leishmaniasis Antigen ● Suspended
SurearlySmartPro COVID-19 ● Completed
2nd Generation G6PD Test ● ● Completed
2nd Generation TB LAM Assay ● ● Suspended
POCT for Multidrug-Resistant TB ● ● In progress
Validation of All-in-One Device for Malaria Diagnosis ● ● Completed
AI-driven All-in-One Diagnostic platform for Malaria Species Differentiation ● ● In progress
POCT for COVID19, Influenza and RSV ● ● ● In progress

*WHO licensure prequalification

Diagnostics(Dx)
Project title Research institute Development stage
Early Validation Late Validation Clinical Validation Licensure
Instrument-free molecular diagnostic platform for COVID-19 ● ●
Mobile Diagnostic Platform for Influenza and SARS-CoV-2 ● ●
Quantitative POC Test Using mBFPfor G6PD Deficiency ●
Rapid Diagnostic Test for Chikungunya Antigen ●
SurearlySmartPro COVID-19 ●
2nd Generation G6PD Test ● ●
Validation of All-in-One Device for Malaria Diagnosis ● ●
POCT for Pyrazinamide (PZA) Susceptibility Testing ●

*WHO licensure prequalification

Diagnostics(Dx)
Project title Research institute Development stage
Early Validation Late Validation Clinical Validation Licensure
AI-driven All-in-One Diagnostic platform for Malaria Species Differentiation ● ●
POCT for COVID19, Influenza and RSV ● ● ●
POCT for Multidrug-Resistant TB ● ●

*WHO licensure prequalification

Diagnostics(Dx)
Project title Research institute Development stage
Early Validation Late Validation Clinical Validation Licensure
Leishmaniasis RDT Cartridge and Mobile Pocket Analyzer ●
Rapid Diagnostic Test for Both S.Typhiand S.ParatyphiA ● ●
Rapid Diagnostic Test for Visceral Leishmaniasis Antigen ●
In vitro Diagnostics Test for Severe Fever and thrombocytopenia Syndrome ●
2nd Generation TB LAM Assay ● ●

*WHO licensure prequalification

Digital Health(DH)
Project title Research institute Development stage Current state
Early Validation Late Validation Clinical Validation Licensure
AI-Driven Platform for Anti-Tubercular Drug Discovery ● Completed
Data Platform to Improve Diagnosis of Infectious Diseases ● Completed
ICT based Self-risk Assessment Platform for COVID-19 ● Completed
Chest X-ray AI for COVID-19 ● Suspended

*WHO licensure prequalification

Digital Health(DH)
Project title Research institute Development stage
Early Validation Late Validation Clinical Validation Licensure
Validation of All-in-One Device for Malaria Diagnosis ●
Data Platform to Improve Diagnosis of Infectious Diseases ●
ICT based Self-risk Assessment Platform for COVID-19 ●
No information yet.

*WHO licensure prequalification

Digital Health(DH)
Project title Research institute Development stage
Early Validation Late Validation Clinical Validation Licensure
Chest X-ray AI for COVID-19 ●
Evidence Generation Award In progress
Project title Research institute Study Area/Country
The impact of digital health technologies on the delivery of maternal and child health services; A case study of Uganda Uganda
DigiHLab: Assessment of digital health tools for laboratory diagnosis of endemic and pandemic diseases Mozambique
Multidisciplinary analysis of digitally preventable health system gap for crisis-affected population in Ethiopia, Nepal, and Kiribati Ethiopia, Nepal, Kiribati
The PAMODZI COVID 19 study: The public health assessment of Malawi’s one digitized infrastructure COVID 19 Study Malawi
Digital tools applicability for community surveillance of infectious disease Nigeria
EVALUATE: Estimating the value-add of Lunit software’s use to accelerate TB elimination Vietnam
Understanding the end-user perspectives of implementing TB-CAD in high TB burden settings and improving fit for use in children Mongolia, Vietnam
No information yet.
No information yet.
Evidence Generation Award
Project title Research institute Study Area/Country Current state
The impact of digital health technologies on the delivery of maternal and child health services; A case study of Uganda Uganda In progress
DigiHLab: Assessment of digital health tools for laboratory diagnosis of endemic and pandemic diseases Mozambique In progress
Multidisciplinary analysis of digitally preventable health system gap for crisis-affected population in Ethiopia, Nepal, and Kiribati Ethiopia, Nepal, Kiribati In progress
The PAMODZI COVID 19 study: The public health assessment of Malawi’s one digitized infrastructure COVID 19 Study Malawi In progress
Digital tools applicability for community surveillance of infectious disease Nigeria In progress
EVALUATE: Estimating the value-add of Lunit software’s use to accelerate TB elimination Vietnam In progress
Understanding the end-user perspectives of implementing TB-CAD in high TB burden settings and improving fit for use in children Mongolia, Vietnam In progress

Receive newsletters from the RIGHT Foundation by e-mail